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Is carotid artery stenting a fair alternative to
carotid endarterectomy for symptomatic carotid
artery stenosis? A commentary on the AHA/ASA
guidelines
Kosmas I. Paraskevas, MD,a Frank J. Veith, MD, FACS,b,c Thomas S. Riles, MD, FACS,d and
Wesley S. Moore, MD, FACS,e Athens, Greece; New York, NY; Cleveland, Ohio; and Los Angeles, Calif
The recent guidelines by the American Heart Association/American Stroke Association (AHA/ASA) and several other
associations recommended carotid artery stenting (CAS) as an alternative to carotid endarterectomy (CEA) for
symptomatic patients (Class I; Level of Evidence: B). The term “alternative” may easily be misinterpreted as “equivalent”
to justify the widespread use of CAS. However, current evidence indicates that for symptomatic patients, CAS produces
inferior outcomes compared with CEA. It is likely that with technical improvements, better patient selection, and better
physician experience, CAS outcomes will improve in the future. CAS may then become a fair alternative to CEA, at least
in certain patient subgroups. Based on current evidence, however, we are not there yet and it seems unfair to spin the
AHA/ASA guidelines to conclude that we are. ( J Vasc Surg 2011;54:541-3.)
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rIn medicine, like politics, the “data” or “facts” can be
interpreted in more than one way. This interpretation
or “spin” is often more important than anything else. Ac-
cording to the recent guidelines by the American Heart
Association/American Stroke Association (AHA/ASA)
and several other associations, “carotid artery stenting
(CAS) is indicated as an alternative to carotid endarterec-
tomy (CEA) for symptomatic patients at average or low risk
of complications associated with endovascular intervention
when the diameter of the lumen of the internal carotid
artery is reduced by more than 70% as documented by
noninvasive imaging or more than 50% as documented by
catheter angiography and the anticipated rate of periproce-
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doi:10.1016/j.jvs.2011.05.052ural stroke or mortality is less than 6% (Class I; Level of
vidence B).”1 The recent Carotid Revascularization End-
rterectomy versus Stenting Trial (CREST) results were
sed to support this recommendation.2 However, the facts
eading to this recommendation may have more than one
nterpretation. This commentary addresses another possi-
le interpretation.
AROTID ARTERY STENTING: AN
LTERNATIVE FOR WHOM?
According to Webster’s NewWorld Dictionary, alterna-
ive is defined as “a choice between two things.”3 Thus, in
he AHA/ASA recommendation, the word alternativemay
asily be misinterpreted as equivalent to justify the wide-
pread use of CAS. Current data, however, indicate that
AS should be viewed neither as an “alternative” nor as an
equivalent” treatment option to CEA in the majority of
ymptomatic patients.
In CREST,2 there was no significant difference in the
stimated 4-year rates of the composite primary end point
etween CAS and CEA (7.2% vs 6.8%, respectively; relative
isk [RR], 1.11; 95% confidence interval [CI], 0.81-1.51;
 .51). The composite primary end point, however,
onsisted of stroke, myocardial infarction (MI), or death
rom any cause.2 Although CAS was associated with con-
iderably higher periprocedural stroke rates compared with
EA (4.1% vs 2.3%, respectively; hazard ratio [HR], 1.79;
5% CI, 1.14-2.82; P .012), this was offset by a reduced
isk of MI (1.1% vs 2.3%, respectively; P .032).2 A recent
ubgroup analysis of CREST showed that in symptomatic
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August 2011542 Paraskevas et alpatients, CAS was associated with an almost twofold in-
crease in periprocedural stroke and death rates compared
with CEA (6.0% 0.9% vs 3.2% 0.7%, respectively; HR,
1.89; 95% CI, 1.11-3.21; P  .02).4 Therefore, CAS only
showed equivalence of outcomes with CEA when MIs were
added to strokes. Quality-of-life indices, however, show
that both major and minor strokes are likely to produce
long-term physical limitations (with minor stroke associ-
ated with worse mental and physical health at 1 year),
whereas the effect of periprocedural MI on long-term
physical and mental health is less.2,5
In addition to CREST, several other randomized stud-
ies have demonstrated that in symptomatic patients, CAS is
associated with higher rates of stroke,6-8 as well as recurrent
carotid stenosis rates8-10 (Table 1). CAS is also consider-
ably more expensive than CEA.11 In addition, several re-
cent meta-analyses have concluded that CAS is associated
with inferior outcomes compared with CEA.12-15 Accord-
ing to one meta-analysis (n 13 trials; 7484 patients; 80%
symptomatic),12 CAS is associated with an increased risk of
any stroke compared with CEA (RR, 1.45; 95% CI, 1.06-
1.99; I2  40%). The conclusion reached was that “for
every 1000 patients opting for CAS rather than CEA, 19
more patients would have strokes.”12 These results were
verified in another independent meta-analysis.13 Both
Table 1. RCT results showing higher rates of stroke/deat
Study (year) Study design
EVA-3S7 (2008) 4-year data of EVA-3S
SPACE9 (2008) 2-year data of SPACE
Steinbauer et al8 (2008) Single-center RCT comparing the
long-term results (66  14.2 vs
64  12.1 months, respectively)
of CAS (n  43) with CEA
(n  44)
ICSS6 (2010) 120-day data from 1,710
symptomatic patients
randomized to CAS vs CEA
CREST4 (2011) RCT of 2502 (1181 asymptomatic;
1321 symptomatic) patients to
CEA (n  1240) or CAS
(n  1262)
EVA-3S10(2011) 2-year carotid ultrasound follow-up
data for 242 CAS patients and
265 CEA patients of EVA-3S
CAS, Carotid artery stenting; CEA, carotid endarterectomy; CI, confidence i
EVA-3S, Endarterectomy Versus Angioplasty in patients with Symptomatic
Study; RCT, randomized controlled trial; SPACE, Stent-Protected Angioplmeta-analyses, however, concluded that the superiority of rEA over CAS disappeared in patients70 years. Accord-
ng to a recent large registry (n  47, 752 CAS and CEA
ospitalizations matched by propensity score), the most
ppropriate procedure in symptomatic patients with carotid
rtery stenosis is CEA, whereas CAS appears to be a suitable
inimally-invasive approach for asymptomatic patients.16
According to the recent inter-collegiate Australasian
AS guidelines, “CAS may be considered as a treatment
ption for patients with symptomatic severe carotid steno-
is who are at high risk of stroke but are surgically unsuit-
ble for CEA.”17 This includes specific patient subgroups
nd conditions, namely (1) postradiation therapy, (2) block
issection of the neck, (3) in situ tracheostomy, (4) recur-
ent stenosis following previous CEA, (5) severe cervical
pine arthritis, (6) surgically inaccessible carotid stenosis
eg, obesity and high carotid bifurcation), (7) contralateral
ecurrent laryngeal nerve injury, and (8) contralateral inter-
al carotid artery occlusion.17 Apart from these conditions,
AS should not be considered as an alternative to CEA for
he management of symptomatic carotid stenosis except in
atients 70 years and those participating in randomized
rials.17
Based on the results of meta-analyses,12-15 randomized
ontrolled trials,6-10 and population-based studies,11,16
AS may be an “alternative treatment” but is clearly infe-
d recurrent carotid stenosis after CAS than CEA
Study outcome
ncidence of 30-day stroke/death rate: 15 of the 262 vs 29 of the
265 patients, or 6.2% vs 11.1%, for CEA vs CAS, respectively
(HR, 1.97; 95% CI, 1.06-3.67; P  .03 for CAS vs CEA).
ncidence of 70% recurrent carotid stenosis: 10.7% vs 4.6%, for
CAS vs CEA, respectively; P  .0009; or 11.1% vs 4.6%, for
CAS vs CEA, respectively; P  .0007, in the intention-to-treat
and per-protocol life-table estimates, respectively.
atients undergoing CAS had higher rates of ipsilateral stroke
(four of 42 vs zero of 42 patients, respectively; P  .05) and
70% recurrent carotid stenosis (six of 32 vs zero of 29,
respectively; P  .05) compared with patients undergoing
CEA.
atients undergoing CAS (n828) had a higher (vs CEA,
n821) risk of any stroke (65 vs 35 events, or 7.7% vs 4.1%,
respectively; HR, 1.92; 95% CI, 1.27-2.89; p  0.002), any
stroke or death (72 vs 40 events, or 8.5% vs 4.7%, respectively;
HR, 1.86; 95% CI, 1.26-2.74; P  .0001), all-cause death (19
vs 7 events, or 2.3% vs 0.8%, respectively; HR, 2.76; 95% CI,
1.16-6.56; P  .017).
ymptomatic patients undergoing CAS had a higher incidence of
any periprocedural stroke (37 vs 21 events, or 5.5%  0.9% vs
3.2%  0.7%, respectively; HR, 1.74; 95% CI, 1.02-2.98; P 
0.04) and a higher incidence of any periprocedural stroke or
death (40 vs 21 events or 6.0%  0.9% vs 3.2%  0.7%,
respectively; HR, 1.89; 95% CI, 1.11-3.21; P  .02) compared
with patients undergoing CEA.
he rate of carotid restenosis of 50% or occlusion was higher
after CAS than after CEA (12.5% vs 5.0%, respectively; time
ratio, 0.16; 95% CI, 0.03-0.76; P  0.02).
l; CREST, Carotid Revascularization Endarterectomy versus Stenting Trial;
e Carotid Stenosis; HR, hazard ratio; ICSS, International Carotid Stenting
ersus Carotid Endarterectomy.h an
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an increased incidence of new ipsilateral silent embolic
events after CAS compared with CEA.18-20 In the absence
of data showing comparable risks of stroke and silent em-
boli for CAS, angioplasty and stenting should only be
offered to symptomatic patients when mitigating factors
suggest an unacceptable risk with CEA.
It is likely that CAS will continue to improve with (1)
better patient selection, (2) better embolic protection de-
vices, (3) better stents (membrane or mesh covered), (4)
technical improvements (eg, avoiding aortic arch manipu-
lations), and (5) additional operator experience.19 Adop-
tion of all these may well improve CAS outcomes and make
it a fair alternative to CEA, at least in certain patient
subgroups. However, the current evidence indicates that
we are not there yet, and it seems unfair to spin either
CREST2 or the AHA/ASA guidelines1 to conclude that we
are.
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Richard P. Cambria, MD, Robert Zwolak, MD, and Peter Gloviczki, MD, Boston, Mass; Lebanon, NH;
and Rochester, Minn
Is carotid artery stenting (CAS) a fair alternative to carotid
endarterectomy (CEA) for symptomatic carotid stenosis? In theoore review the available evidence and conclude the answer is
no” regardless of the context of the recently published American
eart Association/American Stroke Association (AHA/ASA)
